Brief: Biocartis Announces FDA Clearance For Idylla MSI Test
02/03/2023 06:17
March 2 (Reuters) - Biocartis Group NV BCART.BR :
* BIOCARTIS ANNOUNCES US FDA 510(K) CLEARANCE FOR IDYLLA MSI
TEST
* BIOCARTIS CEO: BOTH LARGE AND SMALL US LABS ARE EXPECTED
TO
BENEFIT FROM THIS FAST AND EASY TO USE IDYLLA MSI TESTING
Source text for Eikon: ID:nGNE3ZD3RY
Further company coverage: BCART.BR
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;;))
Recent news on Biocartis NV
See all newsBrief: Biocartis Group NV Appoints Randy Polonsky As Chief Financial Officer
Brief: Biocartis Appoints New Chief Business Officer, VP Global Marketing
Brief: Biocartis And Merck To Collaborate
Brief: Biocartis's Secured Creditors Enforced Their Security Over Subsidiaries Shares
Brief: Biocartis Announces Expansion Of Its Collaboration With Apis Assay Technologies